All In Biotech

Drug Trial Radar · NCT05110196

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients With Mesenchymalepithelial Transition (MET) Exon 14 Skipping Mutation Positive Advanced Nonsmall Cell Lung Cancer (NSCLC).

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Sep 3, 2022

Primary completion

Aug 4, 2025

Study completion Aug 4, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Drugs Controller General of India (DCGI) granted approval for Rahika® (capmatinib) film-coated tablets (150 mg and 200 mg) for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. As a condition of approval, the DCGI required the conduct of a Phase IV clinical trial in Indian patients. As recommended by the DCGI, this Phase IV study was planned to evaluate the safety and efficacy of capmatinib in adult Indian patients with advanced or metastatic NSCLC with MET exon 14 skipping mutation-positive disease, in any line of therapy.

Conditions

  • Non-Small Cell Lung Carcinoma

Interventions

  • Capmatinib 150 mgDrug

    Capmatinib film-coated tablet 150 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

  • Capmatinib 200 mgDrug

    Capmatinib film-coated tablet 200 mg administered BID with or without food for 24 weeks. It should be swallowed whole and should not be broken, chewed, or crushed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events (Serious TEAEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months
  2. Percentage of Participants With Dose ModificationsTime frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months
  3. Dose IntensityTime frame: From first dose of study treatment administration until end of treatment, assessed up to approximately 6 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Puducherry, India

  • Novartis Investigative Site

    Gujarat, Gujarat, India

  • Novartis Investigative Site

    Mangalore, Karnataka, India

  • Novartis Investigative Site

    Thalassery, Kerala, India

  • Novartis Investigative Site

    Trivandrum, Kerala, India

  • Novartis Investigative Site

    Bhopal, Madhya Pradesh, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    Pune, Maharashtra, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Bhubaneswar, Odisha, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

  • Novartis Investigative Site

    Varanasi, Uttar Pradesh, India

  • Novartis Investigative Site

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.